PaxVax has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.
PaxVax will license intellectual property and work together with distinguished professor in the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the university’s Department of Cellular and Molecular Medicine to select the optimal vaccine combination and take this vaccine candidate into clinical trials.
Financial terms of the collaboration were not disclosed.
HSV is one of the most common sexually transmitted diseases in the United States and throughout the world, with approximately 750,000 new infections annually in the U.S. alone.
PaxVax’s proprietary vector-based technology platform, which would be leveraged to develop the HSV vaccine, has helped the company develop several vaccine candidates that have reached clinical trials, including candidates for pandemic influenza, HIV, and anthrax.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity